Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion Therapeutics Gets Relative Strength Rating Upgrade
12:00am, Tuesday, 24'th Mar 2020Esperion announces presentations on NEXLETOL program, NEXLIZET study ESPR
11:49am, Monday, 23'rd Mar 2020
Esperion announces presentations on NEXLETOL program, NEXLIZET study ESPR
ANN ARBOR, Mich., March 23, 2020 -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2.
ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of...
Esperion Announces Pooled Analyses from Phase ' LDL-C Lowering Development Program of the ...
12:00am, Monday, 23'rd Mar 2020Bank of Montreal Can Acquires 1,000 Shares of Esperion Therapeutics Inc (NASDAQ:ESPR)
09:30am, Sunday, 22'nd Mar 2020
Bank of Montreal Can boosted its holdings in Esperion Therapeutics Inc (NASDAQ:ESPR) by 36.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
Esperion appoints Alan Fuhrman to board of directors ESPR
12:03pm, Wednesday, 18'th Mar 2020
Esperion appoints Alan Fuhrman to board of directors ESPR
